Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000949 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3
A Phase 3 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
- 15
- Study locations
NCT00000949: Completed Phase 3 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000949 is a Phase 3 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 460 participants, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000949, a Phase 3 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to examine how rIL-2 affects HIV-positive patients with CD4 counts over 300 cells/mm3 who are on anti-HIV drug therapy. The drug rIL-2 has been shown to increase CD4 cell counts, which help the body fight off HIV. There is strong evidence that rIL-2 increases CD4 cell counts (cells of the immune system that fight infection). This study examines the effect of 2 different amounts of rIL-2 on CD4 cell count and the amount of HIV in the blood (viral burden).
Conditions Studied
Interventions
- DRUG Aldesleukin
Study Locations (15)
Michigan
- Wayne State Univ - WSU/DMC / Univ Hlth Ctr - Detroit
- Henry Ford Hosp - Detroit
New Jersey
- Southern New Jersey AIDS Clinical Trials - Camden
- North Jersey Community Research Initiative - Newark
California
- Community Consortium / UCSF - San Francisco
Colorado
- Denver CPCRA / Denver Public Hlth - Denver
District of Columbia
- Washington Reg AIDS Prog / Dept of Infect Dis - Washington D.C.
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
Illinois
- AIDS Research Alliance - Chicago - Chicago
Louisiana
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Est. Completion | 2000-07 |
| Phase | Phase 3 |
What the finished NCT00000949 record still lists
NCT00000949 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Aldesleukin is the first listed.
NCT00000949 lists 15 locations in 13 states (Michigan, New Jersey, California).
Frequently Asked Questions
What is clinical trial NCT00000949 about?
NCT00000949 is a clinical study titled "A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3". The purpose of this study is to examine how rIL-2 affects HIV-positive patients with CD4 counts over 300 cells/mm3 who are on anti-HIV drug therapy. The drug rIL-2 has been shown to increase CD4 cell counts, which help the body fight off HIV. There is strong evidence that rIL-2 increases CD4 cell c...
What is the current status of trial NCT00000949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. Estimated completion is 2000-07.
What conditions does trial NCT00000949 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000949?
The interventions under investigation include: Aldesleukin (DRUG).
Who is sponsoring clinical trial NCT00000949?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000949 being conducted?
This trial has 15 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000949's enrollment target sits among peer trials
460 71st of 542 higher than 472 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE